Latest news with #NATR
Yahoo
a day ago
- Business
- Yahoo
Nature's Sunshine Products (NASDAQ:NATR) shareholders have earned a 18% CAGR over the last three years
Explore Nature's Sunshine Products's Fair Values from the Community and select yours By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, Nature's Sunshine Products, Inc. (NASDAQ:NATR) shareholders have seen the share price rise 63% over three years, well in excess of the market return (49%, not including dividends). On the other hand, the returns haven't been quite so good recently, with shareholders up just 26%. So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over the last three years, Nature's Sunshine Products failed to grow earnings per share, which fell 0.3% (annualized). Based on these numbers, we think that the decline in earnings per share may not be a good representation of how the business has changed over the years. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics. Do you think that shareholders are buying for the 2.0% per annum revenue growth trend? We don't. While we don't have an obvious theory to explain the share price rise, a closer look at the data might be enlightening. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Take a more thorough look at Nature's Sunshine Products' financial health with this free report on its balance sheet. A Different Perspective It's nice to see that Nature's Sunshine Products shareholders have received a total shareholder return of 26% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 10% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Nature's Sunshine Products you should know about. Of course Nature's Sunshine Products may not be the best stock to buy. So you may wish to see this free collection of growth stocks. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
27-06-2025
- Business
- Yahoo
Why Nature's Sunshine (NATR) Shares Are Getting Obliterated Today
Shares of wellness products company Nature's Sunshine (NASDAQ:NATR) fell 8.5% in the afternoon session after the company announced the pricing of a secondary stock offering by a major shareholder. The offering involves major shareholder Fosun Pharma USA selling up to 2.85 million shares at a price of $12.00 per share. The stock is trading down to align with the offering price, which represents a significant discount to its previous closing price. While the company itself is not selling any new shares and will not receive any proceeds, the large block of stock hitting the market is creating selling pressure. Nature's Sunshine did note that it may buy back up to $15 million worth of shares from the offering as part of its existing repurchase program, which could help absorb some of the supply. The shares closed the day at $14.30, down 3.1% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Nature's Sunshine? Access our full analysis report here, it's free. Nature's Sunshine's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 7.2% on the news that CEO Terrence Moorehead, announced his decision to step down from his role. The board also announced the search for his successor, and Moorehead will remain in his role until a new CEO is appointed. This interim period introduced leadership uncertainty, something the market generally dislikes. Nature's Sunshine is down 4.3% since the beginning of the year, and at $13.94 per share, it is trading 20% below its 52-week high of $17.43 from November 2024. Investors who bought $1,000 worth of Nature's Sunshine's shares 5 years ago would now be looking at an investment worth $1,758. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-06-2025
- Business
- Business Insider
Nature's Sunshine files to sell 2.85M shares of common stock for holders
16:35 EDT Nature's Sunshine (NATR) files to sell 2.85M shares of common stock for holders Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
05-06-2025
- Business
- Yahoo
1 Safe-and-Steady Stock with Exciting Potential and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two stuck in limbo. Rolling One-Year Beta: 0.77 Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Cautious About NATR? Flat sales over the last three years suggest it must innovate and find new ways to grow Modest revenue base of $456.6 million gives it less fixed cost leverage and fewer distribution channels than larger companies Earnings per share fell by 20.6% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine's stock price of $14.13 implies a valuation ratio of 18.5x forward P/E. Dive into our free research report to see why there are better opportunities than NATR. Rolling One-Year Beta: 0.45 The first homebuilder to be listed on the NYSE, KB Home (NYSE:KB) is a homebuilding company targeting the first-time home buyer and move-up buyer markets. Why Do We Avoid KBH? Backlog has dropped by 22.9% on average over the past two years, suggesting it's losing orders as competition picks up Earnings per share have dipped by 5.3% annually over the past two years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 5.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $52.29 per share, KB Home trades at 6.6x forward P/E. Read our free research report to see why you should think twice about including KBH in your portfolio, it's free. Rolling One-Year Beta: 0.32 With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. Why Is UNH a Top Pick? Massive revenue base of $410.1 billion gives it meaningful leverage when negotiating reimbursement rates Share buybacks catapulted its annual earnings per share growth to 13.1%, which outperformed its revenue gains over the last five years ROIC punches in at 21.6%, illustrating management's expertise in identifying profitable investments UnitedHealth is trading at $300.85 per share, or 9.7x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
NATR Q1 Earnings Call: Outperformance Driven by Asia-Pacific and Europe Amid Tariff Uncertainty
Wellness products company Nature's Sunshine (NASDAQ:NATR) announced better-than-expected revenue in Q1 CY2025, with sales up 2% year on year to $113.2 million. The company expects the full year's revenue to be around $457.5 million, close to analysts' estimates. Its non-GAAP profit of $0.25 per share was 51.5% above analysts' consensus estimates. Is now the time to buy NATR? Find out in our full research report (it's free). Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat) Adjusted EPS: $0.25 vs analyst estimates of $0.17 (51.5% beat) Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat) The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million Operating Margin: 5.4%, up from 4.2% in the same quarter last year Free Cash Flow was $1.5 million, up from -$1.5 million in the same quarter last year Market Capitalization: $272.9 million Nature's Sunshine's first quarter results were shaped by continued strength in Asia-Pacific and Europe, as well as stabilization efforts in North America. Management credited growth in Japan and Taiwan to strategic marketing, a focus on high-velocity products, and expanded digital offerings, noting that digital sales rose 19% year over year. CEO Terrence Moorehead emphasized that proactive supply chain measures and inventory buildup helped the company manage new tariff risks without immediate price increases to customers. Looking ahead, management reaffirmed its full-year revenue guidance, citing confidence in ongoing demand and the resilience of its supply chain. CFO Shane Jones noted that the company's outlook remains conservative due to macroeconomic volatility and potential tariff impacts, but expects modest gross margin improvement and stable SG&A expenses. Moorehead stated, 'We've tried to do our homework on our end to make sure that we've done everything that we can do to prepare to potential impact of tariffs.' Nature's Sunshine's management focused on operational execution and regional momentum as key drivers behind Q1's performance. Outperformance versus analyst expectations was attributed to international growth, digital expansion, and effective cost controls, while the company's proactive response to tariff risks was a recurring theme. Asia-Pacific momentum: The region saw double-digit local currency growth, with Japan and Taiwan both delivering over 18% sales increases, driven by a targeted marketing mix and growth-focused product strategy. Europe growth strategies: Central Europe's 16% sales rise was supported by the power line product focus and expansion into the Baltic states, illustrating disciplined execution and market development. North America stabilization: Despite a year-over-year decline, North America achieved its third consecutive quarter of sequential order growth, aided by organizational changes and improved digital capabilities. Digital and autoship adoption: Digital sales outpaced the broader supplement industry's growth, and the Subscribe & Thrive autoship program accounted for about 26% of total sales, supporting recurring revenue. Tariff mitigation measures: The company increased raw and finished goods inventory, diversified suppliers, and enforced pricing contracts to minimize tariff exposure and supply chain disruption. Management expects ongoing uncertainty from tariffs and consumer sentiment to shape results this year, but highlights digital growth and cost discipline as key levers. Strategic investments in digital tools and field support are expected to foster resilience and incremental growth across markets. Digital expansion focus: The rollout of new digital toolkits in North America and continued investment in e-commerce capabilities are expected to drive customer acquisition and retention. Inventory and supply chain agility: Elevated inventory levels and supplier diversification are designed to protect margins and service levels if tariff or trade conditions deteriorate. Cost management discipline: Continued scrutiny of SG&A expenses and margin improvement initiatives are projected to support operating profit even in a challenging macroeconomic environment. Brian Holland (Davidson): Asked if guidance assumes a worsening macro backdrop or a continuation of current trends. Management said the midpoint reflects ongoing instability, while the upper end assumes Q1 trends continue. Brian Holland (Davidson): Inquired about the digital toolkit launch timing and risk of order disruption. CEO Moorehead said it remains on track for the second half of the year and will not disrupt practitioner workflows. Susan Anderson (Canaccord Genuity): Asked about sustaining momentum in Europe and Asia given strong recent comps. Management sees continued opportunity but acknowledged tougher comparisons in the back half of the year. Susan Anderson (Canaccord Genuity): Questioned strategies for North America practitioner and retailer channels. Moorehead highlighted new leadership, field fundamentals, and digital tools as key to improving performance. Susan Anderson (Canaccord Genuity): Sought clarity on gross margin and SG&A cadence. CFO Jones expects modest sequential gross margin improvement and steady quarterly SG&A at $40–42 million. In the quarters ahead, the StockStory team will monitor (1) the rollout and practitioner adoption of new digital toolkits in North America, (2) whether Asia-Pacific and Europe can sustain their growth trajectory against tougher year-over-year comparisons, and (3) the effectiveness of inventory and supply chain strategies in mitigating tariff-related cost pressures. We will also watch for evidence that digital and autoship programs continue to drive recurring revenue. Nature's Sunshine currently trades at a forward P/E ratio of 19.2×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
